MoonLake Immunotherapeutics MLTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$259.47M-75.5% | -$230.32M-90.0% | -$213.7M-158% | -$179.12M-208% | -$147.83M-223% | ||
| $3.08M+115% | $2.62M+88.9% | $2.23M+61.4% | $1.84M+77.6% | $1.44M+107% | ||
| $23.96M+204% | $12.9M+77.1% | $11.24M+61.7% | $9.38M+43.4% | $7.9M+27.2% | ||
| $11.37M— | $20.56M— | —— | —— | —— | ||
| —— | —— | $13.66M— | $2.91M— | $6.42M— | ||
| —— | —— | —— | —— | $1.7M— | ||
| —— | —— | —— | $1.33M+1,207% | -$10K-111% | ||
| $9.81M— | -$561K— | $8.67M— | —— | —— | ||
| -$43K-1,333% | -$58K-5,900% | -$23K+38.3% | -$7K+88.2% | -$3K+95.8% | ||
| -$1.36M-6.6% | -$1.22M+14.1% | -$1.4M-43.0% | -$1.14M-32.0% | -$1.27M-116% | ||
| $2.77M+85.7% | $2.03M+13.4% | $1.61M-4.3% | $1.73M+63.8% | $1.49M+33.6% | ||
| -$224.15M-60.4% | -$196.01M-68.1% | -$185.69M-131% | -$166.42M-158% | -$139.78M-187% | ||
| —— | —— | —— | —— | $343K-30.8% | ||
| $235.89M-32.8% | $265.37M-24.2% | $353.15M+73.7% | $382.33M+9.3% | $351.11M+33.3% | ||
| $382.74M— | $468.4M— | —— | —— | —— | ||
| —— | —— | $85.57M— | —— | —— | ||
| —— | —— | —— | —— | $73.02M— | ||
| —— | —— | —— | —— | —— | ||
| $103.52M+40.9% | $146M+185% | $73.75M-7.3% | $73.46M-7.5% | $73.46M-86.2% | ||
| —— | —— | —— | $1.4M— | —— | ||
| —— | —— | -$24.92M— | —— | —— | ||
| $6.88M— | $5.06M— | $2.87M— | $1.16M— | —— | ||
| —— | —— | $13.66M— | $2.91M— | $6.42M— | ||
| -$1.36M-6.6% | -$1.22M+14.1% | -$1.4M-43.0% | -$1.14M-32.0% | -$1.27M-116% | ||
| $30K— | $0— | $1K— | —— | —— | ||
| $2.77M+85.7% | $2.03M+13.4% | $1.61M-4.3% | $1.73M+63.8% | $1.49M+33.6% | ||
| $9.81M— | -$561K— | $8.67M— | —— | —— | ||
| —— | —— | —— | $1.33M+1,207% | -$10K-111% | ||
| -$43K-1,333% | -$58K-5,900% | -$23K+38.3% | -$7K+88.2% | -$3K+95.8% | ||
| $382.74M— | $468.4M— | —— | —— | —— | ||
| —— | —— | —— | $1.4M— | —— | ||
| -$1.36M-6.6% | -$1.22M+14.1% | -$1.4M-43.0% | -$1.14M-32.0% | -$1.27M-116% | ||
| $567K— | $0— | —— | —— | —— | ||
| -$224.15M-60.0% | -$196.04M-67.4% | -$185.9M-129% | -$166.76M-157% | -$140.12M-185% | ||
| -$224.15M-60.0% | -$196.04M-67.4% | -$185.9M-129% | -$166.76M-157% | -$140.12M-185% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does MoonLake Immunotherapeutics generate?
- MoonLake Immunotherapeutics (MLTX) generated -$224.2M in operating cash flow over the trailing twelve months.
- What is MoonLake Immunotherapeutics's free cash flow?
- After $343.0K of capital expenditures, MoonLake Immunotherapeutics's free cash flow was -$224.2M over the trailing twelve months, down 60.0% year over year.
- Where does MoonLake Immunotherapeutics's cash flow data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.